[
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The Section 10(b)/Rule 10b-5 claim (Count I) is dismissed for failure to plead scienter with particularity under the PSLRA. Plaintiffs rely on vague confidential witness allegations, motive from insider sales, and hindsight from later events, but lack specific contemporaneous facts showing any defendant's actual knowledge that statements were false when made. Innocent explanations (aggressive growth in booming used-car market amid COVID disruptions) are equally plausible. Count II (§20(a)) is dismissed as derivative. Count III (§20(A)) is dismissed absent underlying §10(b) violation. Securities Act claims (Counts IV-VI) are sustained, as they do not require scienter and adequately allege material misstatements/omissions in the Registration Statement regarding unsustainable growth practices.",
      "claim_rulings": [
        {
          "claim": "COUNT I: §10(b)/Rule 10b-5 (Exchange Act Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts show defendants knew statements were false when made. CW accounts are vague (e.g., 'pretty sure,' general complaints in meetings), do not tie specific false statements to individual defendants' knowledge at the time, and reflect mid-level observations rather than executive awareness. Motive from sales (e.g., Garcia II's $3.7B) insufficient alone. Later disclosures (e.g., ADESA purchase, sales decline) are classic 'fraud by hindsight.' General access to metrics insufficient without specifics on falsity timing. No strong scienter inference; business misjudgments plausible."
        },
        {
          "claim": "COUNT II: §20(a) (Exchange Act Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Count I; no primary violation."
        },
        {
          "claim": "COUNT III: §20(A) (Garcia II, Jenkins, Keeton, Huston)",
          "ruling": "dismissed",
          "scienter_analysis": "Requires underlying §10(b) violation (dismissed Count I)."
        },
        {
          "claim": "COUNT IV: §11 (Securities Act Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A (strict liability/negligence; PSLRA inapplicable)."
        },
        {
          "claim": "COUNT V: §12(a)(2) (Securities Act Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A (strict liability/negligence; PSLRA inapplicable)."
        },
        {
          "claim": "COUNT VI: §15 (Individual Securities Act Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A (derivative of §§11/12(a)(2); PSLRA inapplicable)."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 99480,
      "completion_tokens": 555,
      "total_tokens": 100964
    },
    "case_id": "azd-2_22-cv-02126"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint adequately pleads particularized facts establishing that Musk knew his key statements (e.g., 'Funding secured,' 'Investor support is confirmed') were false when made, based on his August 2 email admitting 'a lot of uncertainty' and 50% likelihood of success, the preliminary July 31 PIF meeting with no terms discussed (including price or structure), undisclosed contingencies (e.g., Middle East factory as 'non-starter'), lack of advisors or shareholder outreach, and his impulsive tweeting without review. These create a strong inference of scienter for Musk (intent/recklessness), imputed to Tesla via adoption by IR and Musk's role. Motive to harm shorts reinforces but is not essential. Section 10(b)/Rule 10b-5 claim sustained. Section 20(a) claim dismissed as derivative would fail even if primary survived; no particularized facts of Board's actual knowledge of falsity at statement time, only general oversight duties and post-hoc reactions; conclusory 'awareness' and vague press release insufficient for culpable participation.",
      "claim_rulings": [
        {
          "claim": "Count I: Violation of Section 10(b) and Rule 10b-5 against Tesla and Musk",
          "ruling": "sustained",
          "scienter_analysis": "Particularized facts (e.g., Musk's pre-tweet email on 'uncertainty'/50% odds, no price discussions, preliminary PIF talks, no agreements/advisors) show Musk's actual knowledge of falsity at time of statements. Strong inference of intent/recklessness outweighs innocent optimism (contradicted by his admissions). Imputed to Tesla."
        },
        {
          "claim": "Count II: Violation of Section 20(a) against the Board",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts showing Board members' knowledge of falsity when Musk tweeted (impulsive, unreviewed); relies on conclusory oversight duties, general access, post-tweet actions. No culpable participation; equally plausible innocent explanations (e.g., reactive evaluation)."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 27588,
      "completion_tokens": 425,
      "total_tokens": 30061
    },
    "case_id": "cand-3_18-cv-04865"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead scienter with particularity under the PSLRA for the Section 10(b)/Rule 10b-5 claim. Allegations rely on hindsight (later admissions that sharing contributed to saturation after re-analysis), vague former employee statements without specific contemporaneous knowledge of falsity or quantified sharing data, general corporate monitoring/testing, and evasiveness. No particularized facts show any defendant knew statements (e.g., '60% penetrated' for paid subs, COVID 'pull-forward' explanations) were false when made; innocent explanations (genuine attribution to COVID noise obscuring stable sharing impact until persistent misses) are at least equally plausible. No motive pled (e.g., sales). Group pleading rejected. Section 10(b) claim dismissed; Section 20(a) claim dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "First Claim: Violation of Section 10(b) of the Exchange Act and Rule 10b-5 against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized allegations of contemporaneous knowledge of falsity. '60% UCAN penetration' reflects reported paid subscribers/TAM; no facts show defendants knew/sharers made it '83%' at statement time (Jan. 2021). COVID 'pull-forward'/'choppiness' attributions match later admissions of genuine belief clouded by COVID until 2022 re-analysis. FEs (Program Mgmt/Designer) allege discussions of 'lost revenue' but no specifics/numbers communicated to Individual Defendants or tied to statements. Public monitoring/testing/10-K tweaks show awareness of sharing risk, not knowledge of material omission/falsity. Later quantification ('stable % over years,' '100m+ sharers') is hindsight; no motive. Strong inference absent; dismiss."
        },
        {
          "claim": "Second Claim: Violation of Section 20(a) of the Exchange Act against the Individual Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b) claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 44249,
      "completion_tokens": 422,
      "total_tokens": 46012
    },
    "case_id": "cand-4_22-cv-02672"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint alleges that Defendants made false and misleading statements about Lucid's production capabilities and guidance for 2022, attributing issues to external supply chain problems while concealing severe internal logistics, inventory, and design flaws that prevented meeting targets. Plaintiffs rely on detailed former employee accounts (FEs) of chaos known to management, including Rawlinson's alleged internal admission in Oct/Nov 2021 of producing <10,000 vehicles (contradicting public 20,000 guidance), personal briefings/tours, and core business focus. These provide particularized facts of actual knowledge for Rawlinson at time of key statements (e.g., Nov 2021 reaffirmation). For House, knowledge imputed via position, meetings (e.g., denying inventory counts), and reports, plus corporate scienter. Motive (Rawlinson's options vesting on mkt cap) and core ops strengthen. No mere hindsight/conclusory; innocent explanations (startup pains, real supply issues) plausible but not more so than fraud given concealment, partial disclosures, and specifics. Scienter meets PSLRA 'strong inference' for 10(b). Section 20(a) sustained as derivative.",
      "claim_rulings": [
        {
          "claim": "COUNT I: Violation of Section 10(b)/Rule 10b-5 against all Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Particularized allegations (FE-2's account of Rawlinson's Oct/Nov 2021 internal admission of <10k production, kept confidential; FE-1's direct Sep/Nov 2021 briefings to Rawlinson on warehouse failures preventing goals; multiple FEs confirming meetings/reports/tours showing top mgmt knowledge pre-statements; core ops dependence on Air production) show Defendants knew falsity of guidance (20k then 12-14k) and supply-chain blame when made. Strong inference over innocent ramp-up excuses, as concealment persisted post-cuts."
        },
        {
          "claim": "COUNT II: Violation of Section 20(a) against Individual Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Derivative of sustained 10(b); control alleged via senior roles (CEO/CFO), involvement in statements"
        }
      ]
    },
    "usage": {
      "prompt_tokens": 75198,
      "completion_tokens": 453,
      "total_tokens": 76583
    },
    "case_id": "cand_22_cv_02094"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "Motion to dismiss granted in full. The complaint fails to plead particularized facts giving rise to a strong inference of scienter as required by the PSLRA for the Section 10(b)/Rule 10b-5 claim. Allegations rely on vague CW reports (often hearsay or second-hand), general corporate knowledge, later disclosures (fraud by hindsight), and motive (equity grants), which do not create a strong inference of intent to deceive or recklessness over plausible innocent explanations like mismanagement, optimistic projections, and operational failures in inventory systems and product rollout. Section 20(a) claim dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "First Claim for Relief (Section 10(b) of the Exchange Act and Rule 10b-5(b) against all Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations show defendants knew statements (re: effective internal controls, AviClear success, core business strength) were false when made. CW allegations are conclusory/vague (e.g., 'concerns raised to Mowry' via hearsay chains like 'Batarseh told CW1 she told Mowry'); no specific contemporaneous knowledge of falsity (e.g., documents/meetings admitting issues). Relies on hindsight from restatements/poor results, general 'core operations' inference, and motive (equity grants), which PSLRA rejects. Innocent explanations (negligent rollout, ERP failures, business challenges) equally/more plausible than fraud. Fails strong inference test."
        },
        {
          "claim": "Second Claim for Relief (Section 20(a) of the Exchange Act against the Individual Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b)/Rule 10b-5 claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 65569,
      "completion_tokens": 403,
      "total_tokens": 66676
    },
    "case_id": "cand_23_cv_02560"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The Section 10(b)/Rule 10b-5 and Section 20(a) claims are dismissed for failure to plead scienter with particularity under the PSLRA. The allegations, including the former employee's statements, reflect at most an aggressive business decision based on promising Phase 1 data in a small subset of patients, not actual knowledge of falsity or recklessness. Innocent explanations (optimistic interpretation of Phase 1 results justifying Phase 2 bypass in oncology) are at least equally plausible. No specific contemporaneous facts show defendants knew statements were false when made; claims rely on hindsight from Phase 3 failure, general corporate knowledge, and motive (fundraising). Section 20(a) dismissed as derivative. Securities Act claims under Sections 11 and 15 sustained; no scienter required, and allegations of material misstatements/omissions in the IPO prospectus (e.g., Phase 1 'validated' dosing for Phase 3; inadequate risk disclosure for Phase 2 bypass) state plausible claims surviving Twombly.",
      "claim_rulings": [
        {
          "claim": "Count I: Violation of Section 10(b) and Rule 10b-5 Against Rain, Vellanki, and Bryce",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts show defendants knew statements (e.g., Phase 1 data 'validated' dosing/supports Phase 3; 'late-stage') were false when made. FE1 alleges Vellanki/Bryce 'understood' Phase 1 yielded RP2D (n=16 LPS patients, 3-4x PFS benefit) with limitations and bypass was 'aggressive,' but proceeding reflects debatable judgment, not scienter. No evidence they knew data did not support bypass (common in oncology for rare tumors); articles cited show increased risk, not impossibility. SEC IPO comments on hype/pipeline addressed and revised; post-IPO repetition suggests optimism, not deceit. Sarbox certifications, motive (fundraise/save costs/first-to-market), 'reckless gamble' conclusory. Hindsight (Phase 3 failure, high AEs, CSO post-hoc dose comment) insufficient. General access/positions inadequate. Innocent plausibility (believed data de-risked trial) defeats strong inference."
        },
        {
          "claim": "Count II: Violation of Section 20(a) of the Exchange Act against Vellanki and Bryce",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b)/Rule 10b-5 claim; no underlying violation."
        },
        {
          "claim": "Count III: Violation of Section 11 of the Securities Act against Rain and the Director Defendants",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Section 11 imposes strict liability/negligence standard; no scienter required. Prospectus statements (Phase 1 'validated' dosing/supports Phase 3) and omissions (Phase 2 bypass risks, deviation from standards/Daiichi plan) plausibly material under ordinary standards."
        },
        {
          "claim": "Count IV: Violation of Section 15 of the Securities Act against the Director Defendants",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Section 15 control person claim derivative of Section 11; signing directors plausibly liable absent due diligence defense (not established at pleading stage)."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 30953,
      "completion_tokens": 688,
      "total_tokens": 33305
    },
    "case_id": "cand_23_cv_03518"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint adequately pleads particularized facts supporting a strong inference of scienter for the Section 10(b)/Rule 10b-5 claim, primarily through detailed confidential witness allegations that Defendant Nightingale personally discussed known declines in revenue and traffic from major customers in internal all-hands meetings (e.g., November 2023) shortly before or contemporaneously with contradictory public statements denying such issues. These specific, contemporaneous internal admissions by Nightingale, corroborated by multiple CWs with detailed roles and access, outweigh innocent explanations (e.g., optimism for recovery or guidance ranges), creating a cogent inference of intent or recklessness at least as compelling as non-culpable interpretations under Tellabs. Thus, Count I is sustained against all Defendants. Count II (Section 20(a)) is sustained as derivative of the primary violation.",
      "claim_rulings": [
        {
          "claim": "Count I (Violations of Section 10(b) of the Exchange Act and Rule 10b-5 Against All Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Particularized allegations show Defendants (especially Nightingale) knew statements were false when made: CW1 and CW6 detail Nightingale's November 2023 all-hands statements admitting 'decreasing revenue from big customers,' 'throttled down' usage by large media accounts, and a specific streaming company 'throttling things back, which is why revenue is down'—directly contradicting his Nov. 15 public denial of macro headwinds or slowing growth. Ongoing knowledge via weekly Customer Ops meetings (Nightingale occasionally attended, red/yellow/green traffic ratings, tiger teams), Fastly App tracking, sales quota failures (only 30% met by end-2023), customer cancellations/discounts (e.g., Indeed, USAA), and 2024 comp plan shift to new customers while publicly touting existing customer growth. CW5 alleges Nightingale personally pushed delayed product for Apple/Amazon only in May 2024 despite 2023 promises, undermining May claims of 'progress.' Sarbanes-Oxley certifications and suspicious discontinuation of DBNER/NRR metrics further support recklessness. No mere 'corporate knowledge' or hindsight; specific, temporal facts tie Nightingale's actual contemporaneous knowledge to false statements. Sales by executives add motive but not required. Innocent explanations (e.g., hoped-for rebound, multi-vendor volatility) less plausible than deliberate concealment given direct internal-public contradictions."
        },
        {
          "claim": "Count II (Violations of Section 20(a) of the Exchange Act Against the Individual Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable; Section 20(a) control liability is derivative of underlying Section 10(b) violation, which is adequately pleaded. Individual Defendants' senior roles (CEO/CFO), signing of filings, and participation in calls satisfy control person elements."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 25000,
      "completion_tokens": 586,
      "total_tokens": 27224
    },
    "case_id": "cand_24_cv_03170"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead with particularity facts giving rise to a strong inference of scienter under the PSLRA for the Section 10(b)/Rule 10b-5 claim. The challenged statements are optimistic projections about an expected product ramp with an existing customer, not definitive assertions of a firm contract. Subsequent events (e.g., no immediate ramp, later clarifications) constitute impermissible 'fraud by hindsight.' No particularized facts show defendants knew the statements were false when made; innocent explanations (e.g., tentative customer expectations that did not materialize) are at least as plausible. Insider trading and motive allegations are vague and non-probative. Count One dismissed; Count Two dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count One: Violations of Section 10(b) of the Exchange Act and Rule 10b-5(b) against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations demonstrate defendants knew statements were false when made. Statements (e.g., 'expected to ramp in Q4,' 'significant customer') are forward-looking and qualified, based on anticipated customer adoption of a new design. Plaintiffs rely on conclusory claims of falsity ('no such customer existed'), later non-disclosure/pivots as 'cover-up,' and hindsight (no Q4 ramp occurred). No confidential witnesses, documents, or specifics show knowledge of falsity contemporaneous with July 25, 2023 statements. Motive (stock ownership, insider sales, anti-short pressure) is generic; core operations inference weak. Equally plausible innocent explanation: good-faith expectations from customer discussions/bookings (later confirmed as $30M N-CNR in post-suit release) that delayed. Fails PSLRA strong inference standard."
        },
        {
          "claim": "Count Two: Violations of Section 20(a) of the Exchange Act against Defendant Vinciarelli",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claim derivative of dismissed Section 10(b)/Rule 10b-5 violation; requires underlying primary violation, which is absent."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 11840,
      "completion_tokens": 435,
      "total_tokens": 13128
    },
    "case_id": "cand_24_cv_04196"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead scienter with particularity under the PSLRA for the Section 10(b) and Rule 10b-5 claim. There are no specific, non-conclusory facts showing that Defendants knew statements about the commercial business, FY21 guidance, or product risks were false when made. Allegations rely on hindsight from the January 2022 disclosure of a cracking issue, post-hoc analyst speculation about due diligence, an updated manual, and general corporate access, which are equally consistent with innocent explanations (e.g., the issue 'developed over time' and was identified late via quality assessment amid acknowledged project lumpiness and supply issues). Count I dismissed. Count II, derivative of Count I, also dismissed.",
      "claim_rulings": [
        {
          "claim": "Count I: Violation of §10(b) of the Exchange Act and Rule 10b-5 Against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts show Defendants' actual knowledge of falsity at statement times (Aug/Nov 2021). Conclusory claims of 'knew or disregarded' defects in 'nearly all' systems and cost impacts lack support from witnesses, documents, or specifics. Hindsight from Jan 2022 disclosure ('developed over time,' identified via 'product quality assessment') and analyst guesses ('likely came up in due diligence') do not create strong scienter inference; innocent explanations (late discovery amid lumpy business/delays) at least as plausible. 'Core operations' weak (commercial ~23% revenue). No stock sales or other motives."
        },
        {
          "claim": "Count II: Violation of §20(a) of the Exchange Act Against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Count I; no underlying Section 10(b) violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 20290,
      "completion_tokens": 378,
      "total_tokens": 21584
    },
    "case_id": "cand_3_22-cv-00956"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The motion to dismiss is GRANTED. The complaint fails to plead particularized facts giving rise to a strong inference of scienter under the PSLRA for the Section 10(b)/Rule 10b-5 claim. Many challenged statements are boilerplate risk disclosures that candidly acknowledge the precise risks that materialized (cGMP failures at CMOs and pre-approval inspection risks). Positive statements about 'cGMP-compliant facilities' and 'GMP manufacturing capacity at scale' are puffery or opinions, not rendered false by later Form 483 observations, which do not conclusively establish non-compliance. Allegations of executive knowledge rely on CW reports of delays, meetings, and involvement in mock/FDA inspections, but fail to show actual knowledge that statements were false when made. No specific facts contradict plausible innocent explanations: Defendants reasonably believed issues were being remediated (evidenced by frequent oversight, mock inspections, BLA submission with PPQ data, and post-BLA hedging on approval), disclosed extensive risks, and did not assure approval. This amounts to fraud by hindsight and general corporate knowledge, not scienter. Section 20(a) claim dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "COUNT I (Violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 Against All Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations show Defendants knew statements were false when made. CWs allege Adcock/Sender meetings on delays, Soon-Shiong's BLA review/inspection involvement, and reporting under quality agreements, but these show awareness of operational challenges at CMO, not knowledge of falsity in compliance representations. No specific contemporaneous facts (e.g., internal documents admitting falsity) tie knowledge to statement dates. Reliance on executive experience, core business importance, and group pleading for Sachs insufficient. Innocent explanations (diligent remediation efforts, risk disclosures matching events) equally or more plausible than deceit/recklessness."
        },
        {
          "claim": "COUNT II (Violations of Section 20(a) of the Exchange Act Against the Individual Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b)/Rule 10b-5 claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 33148,
      "completion_tokens": 464,
      "total_tokens": 36762
    },
    "case_id": "casd_3_23-cv-01216"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead particularized facts giving rise to a strong inference of scienter under the PSLRA for any defendant with respect to the alleged misstatements. Allegations rely on post-hoc admissions, confidential witness accounts lacking specificity as to individual defendants' knowledge of falsity at the time, corporate scienter, motive, and core operations inferences, which are insufficient. Fraud-by-hindsight is evident from later disclosures and escalating issue scope. Innocent explanations (prospective process fixes, low V2500 fallout rates, FAA disclosures, modeling) are equally or more plausible. Section 10(b)/Rule 10b-5 claim dismissed; Section 20(a) claim dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Section 10(b)/Rule 10b-5 (RTX and Individual Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized allegations that any defendant knew specific challenged statements were false when made. Hayes' 2023 admissions show 2020 V2500 knowledge and process changes, but plausible belief issue contained (low fallout, modeling, FAA-limited ADs). FEs allege general awareness/cost pressures but no specifics tying individual defendants to contemporaneous GTF knowledge or intent to deceive. Relies on speculation, group pleading, motive. No strong inference over innocent mismanagement."
        },
        {
          "claim": "Count II: Section 20(a) (Individual Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b) claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 62281,
      "completion_tokens": 324,
      "total_tokens": 63852
    },
    "case_id": "ctd-3-23-cv-01035"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead scienter with particularity under the PSLRA for the Section 10(b)/Rule 10b-5 claims. Allegations of repeated guidance reductions constitute impermissible 'fraud by hindsight.' Confidential witness accounts (primarily from non-bioprocessing segments) are vague, second-hand, and do not show particularized knowledge of falsity at the time of specific statements. Optimistic forward-looking guidance about bioprocessing growth is supported by contemporaneous backlogs and orders; innocent explanations (e.g., post-COVID market normalization, volatile demand) are at least equally plausible. No specific facts demonstrate defendants' actual knowledge that statements were false when made. Insider trading is routine (tied to PSUs and 10b5-1 plans); business importance and analyst focus do not suffice. Item 303 omissions fail for lack of scienter. Section 20(a) claims dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Violations of Section 10(b) of the Exchange Act and Rule 10b-5 (against Danaher, Blair, McGrew, Ligner)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized allegations showing any defendant knew specific statements were false when made. CW4's single anecdote of Blair allegedly overriding projections post-Q1 2022 is isolated, not corroborated, and from internal comms role without bioprocessing access. Other CWs from unrelated segments. Guidance revisions reflect evolving market (endemic COVID, funding shifts), not pre-existing knowledge of falsity. Conclusory claims of 'untethered to customer activity' speculative; defendants publicly addressed risks (e.g., pockets of inventory). No strong inference over plausible non-culpable explanations."
        },
        {
          "claim": "Count II: Violations of Section 20(a) of the Exchange Act (against Blair and McGrew)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b) claim; requires underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 36392,
      "completion_tokens": 418,
      "total_tokens": 37819
    },
    "case_id": "dcd-1_23-cv-02055"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The motion to dismiss is GRANTED as to Count I (Section 10(b)/Rule 10b-5) and Count III (Section 20(a)). The motion to dismiss is DENIED as to Count II (Section 14(a)/Rule 14a-9). Counts I and III are dismissed with prejudice. Count II survives because Section 14(a) claims do not require PSLRA-compliant scienter pleading and the complaint pleads material omissions in the Proxy with particularity under Rule 9(b), including specific omissions of conflicts, process irregularities, and bidder interactions supported by cited internal documents (e.g., meeting minutes, offer letters).",
      "claim_rulings": [
        {
          "claim": "Count I: Section 10(b)/Rule 10b-5 against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations show that any defendant knew specific statements (e.g., press release or Proxy claims of 'robust process' and 'independent' Special Committee) were false when made. Allegations rely on group pleading ('Defendants'), speculation (e.g., 'must have known' from deal size or 'core operation'), and motives (e.g., TRA payments, job retention) that are equally consistent with non-culpable conduct. Omissions in Proxy do not establish duty to disclose for seller class under 10b-5, and discrepancies are 'fraud by hindsight' using post hoc documents. No strong inference of scienter; innocent explanations (e.g., good-faith belief in process fairness, partial disclosures in Supplemental Proxy) are at least equally plausible."
        },
        {
          "claim": "Count II: Section 14(a)/Rule 14a-9 against Focus, Special Committee Defendants, Board Defendants, and Officer Defendants",
          "ruling": "sustained",
          "scienter_analysis": "N/A (PSLRA scienter pleading does not apply to Section 14(a) claims)"
        },
        {
          "claim": "Count III: Section 20(a) against Special Committee Defendants, Board Defendants, and Officer Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b)/Rule 10b-5 claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 33685,
      "completion_tokens": 462,
      "total_tokens": 36265
    },
    "case_id": "dde_ 23_cv_1466"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead with particularity facts giving rise to a strong inference of scienter as required by the PSLRA. Allegations rely on corporate scienter, group pleading, fraud by hindsight from post-Class Period events (e.g., DOJ complaint, MDL rulings), and speculation about defendants' knowledge rather than specific contemporaneous facts showing actual knowledge of falsity at the time of statements. Innocent explanations (e.g., belief post-declination that no material liability; partial disclosures of opioid-related governmental inquiries and MDL) are at least equally plausible. Section 10(b)/Rule 10b-5 claim dismissed; Section 20(a) claim dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Section 10(b) and Rule 10b-5 against all Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized allegations of specific facts showing defendants knew statements (e.g., SEC filings claiming all reasonably possible material liabilities disclosed; risk factors; stewardship PR; SOX certs) were false when made. Relies on pre-Class Period docs (e.g., 2014 PSW), general committee membership, signing filings, and hindsight from 2020 disclosures/MDL. McMillon's alleged DOJ involvement (2018) lacks specifics tying to filing knowledge. Partial disclosures (e.g., opioid subpoenas in 1Q18 10-Q, MDL) and post-declination (Aug 2018) support plausible non-culpable inference of immateriality."
        },
        {
          "claim": "Count II: Section 20(a) against Individual Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b)/Rule 10b-5 claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 44368,
      "completion_tokens": 369,
      "total_tokens": 45722
    },
    "case_id": "dde_21_cv_55"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "Count II alleging violations of Section 10(b) and Rule 10b-5 is dismissed with prejudice for failure to plead scienter with particularity as required by the PSLRA. All other counts are sustained, as they are adequately pleaded under applicable pleading standards (no scienter required for Count I; Rule 9(b) and Iqbal/Twombly satisfied for state law and CEA claims with specific allegations of misrepresentations, events, and conduct).",
      "claim_rulings": [
        {
          "claim": "Count I (Securities Act §§ 77e, 77l(a)(1) against CFT, FxWinning)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Strict liability claim; no scienter required. Investment accounts adequately alleged as unregistered 'investment contracts' under Howey."
        },
        {
          "claim": "Count II (Exchange Act § 10(b)/Rule 10b-5 against CFT, FxWinning, de Rocha, Cardenas, Brito Cutie)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations showing defendants knew statements were false when made. Relies on conclusory 'upon information and belief' that no trades occurred, fake audit/KPMG report, no regulation/CMI (paras. 107-110), without contemporaneous sources, documents, or witnesses. 'Knew or should have known' language (para. 112) inadequate. Subsequent withdrawal blocks, personal withdrawals, property purchases, and articles are 'fraud by hindsight' and motive/opportunity, not strong inference. Innocent explanations (e.g., liquidity crisis, genuine KYC/AML issues, business failure) equally plausible. Fails PSLRA standard."
        },
        {
          "claim": "Count III (Commodity Exchange Act §§ 6b, 6e, 6o, 25 against CFT, FxWinning, de Rocha, Cardenas, Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Non-PSLRA claim. Fraudulent forex/commodity pool adequately alleged with specific misrepresentations and scheme."
        },
        {
          "claim": "Count IV (Florida Securities Act §§ 517.301, 517.211 against CFT, FxWinning, de Rocha, Cardenas, Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - State law claim not subject to PSLRA. Specific violations and misrepresentations pleaded with particularity under Rule 9(b)."
        },
        {
          "claim": "Count V (Breach of Contract against FxWinning)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Contract claim; no scienter required."
        },
        {
          "claim": "Count VI (Breach of Fiduciary Duty against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Fiduciary duty claim adequately alleges duties from power-of-attorney/fund control and breaches."
        },
        {
          "claim": "Count VII (Fraud in the Inducement against CFT, FxWinning, de Rocha, Cardenas, Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Common law fraud; Rule 9(b) satisfied by detailed misrepresentations (Telegram, websites, events), reliance, and damages."
        },
        {
          "claim": "Count VIII (Negligent Misrepresentations against CFT, FxWinning, de Rocha, Cardenas, Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Negligence claim; no scienter required."
        },
        {
          "claim": "Count IX (Conversion against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Conversion adequately alleged via refusal to return identifiable funds."
        },
        {
          "claim": "Count X (Unjust Enrichment against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Quasi-contract claim; benefit conferred and unjust retention pleaded."
        },
        {
          "claim": "Count XI (Civil Conspiracy against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "N/A - Conspiracy adequately alleged with common purpose, specific roles, and overt acts."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 15671,
      "completion_tokens": 885,
      "total_tokens": 19006
    },
    "case_id": "flsd-1_23-cv-23139"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The Section 10(b)/Rule 10b-5 claim (Count 1) is sustained against ATI, Diab, and Jordan due to particularized allegations from confidential witnesses (FE-1, FE-4) establishing their receipt of weekly/monthly reports and participation in meetings discussing high attrition rates (41%) prior to and during the Class Period, creating a strong inference of knowledge that statements touting 'high retention/low turnover' and financial projections were false when made. Scienter is not adequately pleaded against McKnight, lacking specific facts tying him to contemporaneous knowledge of falsity; claim dismissed as to him. Section 20(a) (Count 2) sustained against Diab and Jordan as derivative of sustained 10(b) claim, dismissed as to McKnight. Section 14(a)/Rule 14a-9 claim (Count 3) sustained against all Defendants under negligence standard, as proxy materials contained material misstatements/omissions regarding retention rates, compensation, risks (presented as hypothetical but actual), and projections. Section 20(a) proxy claim (Count 4) sustained as derivative.",
      "claim_rulings": [
        {
          "claim": "Count 1: Section 10(b)/Rule 10b-5 against ATI and ATI Individual Defendants (Diab, Jordan, McKnight)",
          "ruling": "sustained (as to ATI, Diab, Jordan; dismissed as to McKnight)",
          "scienter_analysis": "Particularized facts from FE-1 (Talent Acquisition Specialist reporting chain to Diab) allege Diab and Jordan attended quarterly meetings discussing attrition and received weekly reports showing ~41% rate (twice industry avg) throughout late 2020/early 2021 Class Period; FE-4 (Senior Financial Analyst) prepared monthly CFO/Board decks with attrition trend graphs for Jordan showing declining headcount. Combined with core operations (therapist retention vital to revenue/clinic growth), SARs (sharp July 2021 guidance cut attributing to Q2 'acceleration' despite prior knowledge), executive terminations (Diab/Coco), and SEC probe, creates strong inference of actual knowledge/recklessness as to falsity of retention boasts (e.g., Feb. 22 'very high retention/low turnover') and projections at time made. No such specific facts for McKnight (FVAC CEO/pre-merger); general access insufficient, innocent explanations (e.g., post-merger director unaware of internal data) equally plausible."
        },
        {
          "claim": "Count 2: Section 20(a) against ATI Individual Defendants (Diab, Jordan, McKnight)",
          "ruling": "sustained (as to Diab, Jordan; dismissed as to McKnight)",
          "scienter_analysis": "Derivative of Count 1; requires underlying 10(b) violation."
        },
        {
          "claim": "Count 3: Section 14(a)/Rule 14a-9 against All Defendants",
          "ruling": "sustained",
          "scienter_analysis": "N/A (negligence claim disclaiming fraud/scienter; material misstatements in Proxy Solicitations re: 'high/strong retention,' 'competitive compensation,' hypothetical risks (attrition/labor costs already occurring at 41%), unattainable projections ($731M revenue/$119M EBITDA), overstated goodwill/intangibles; omissions of known attrition trend violating proxy duties."
        },
        {
          "claim": "Count 4: Section 20(a) (Proxy) against ATI Individual Defendants and FVAC Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Derivative of Count 3; requires underlying 14(a) violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 30291,
      "completion_tokens": 733,
      "total_tokens": 33296
    },
    "case_id": "ilnd-1-21-cv-04349"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead scienter with particularity under the PSLRA for the Section 10(b)/Rule 10b-5 claim. Although CW1 provides some details about potential bias known to LeBel via investigator reports and online dissemination of criteria, there are no specific facts establishing the timing of defendants' actual knowledge relative to the challenged statements (e.g., no dates when investigators contacted LeBel or when company personnel reviewed forum posts). Allegations rely on inferences from CW1's general statements about 'Defendants' knowing of bias, group pleading for corporate knowledge, speculation that senior executives 'must have known' due to importance of the trial, and Lucchino's stock sales (which began pre-Class Period, lack details on total holdings or Rule 10b5-1 plans, and are equally consistent with routine diversification). Core operations allegations and later disclosures of bias smack of 'fraud by hindsight.' Innocent explanations—suspected but unconfirmed risk of bias (disclosed in 10-Q), hope for positive data signal despite design flaws, and prompt self-disclosure upon topline results—are at least equally plausible. Count I dismissed; Count II dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Violations of §10(b) of the Exchange Act and Rule 10b-5 (Against All Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts show defendants knew statements were false when made. CW1 alleges investigators reported discrepancies to LeBel and company knew of online criteria dissemination, but lacks timing tying knowledge to Class Period statements. No specific contemporaneous knowledge of 'hopeless' bias; forward-looking statements protected. Stock sales and core operations do not create strong inference over innocent explanations (optimism, disclosed risks, self-disclosure)."
        },
        {
          "claim": "Count II: Violations of §20(a) of the Exchange Act (Against the Individual Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Count I; requires underlying §10(b) violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 16572,
      "completion_tokens": 421,
      "total_tokens": 20160
    },
    "case_id": "mad-1-21-cv-10933"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "All claims dismissed. The complaint fails to plead particularized facts giving rise to a strong inference of scienter as required by the PSLRA for the Section 10(b) and Rule 10b-5 claims. Allegations rely on general corporate knowledge, CW accounts lacking direct ties to defendants' contemporaneous awareness of falsity, access to generic reports without specifics contradicting particular statements, hindsight from post-Class Period events (e.g., Quinn Report, crash), and suspicious resignations. Innocent explanations (optimism about progress, manageable issues in emerging tech, regulatory permits obtained) are at least equally plausible. No specific facts show defendants knew statements touting 'Level 4,' 'fully driverless,' or safety were false when made over multi-year period. Post-crash cover-up shows poor judgment but not strong scienter for prior statements. Section 20(a) claims dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "COUNT I: Section 10(b)/Rule 10b-5(b) against GM, Cruise, and Individual Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized allegations of defendants' actual knowledge of falsity at time of statements (e.g., pre-2022 touts). CWs provide generalized safety concerns without dates tying to specific statements or defendants' review. Risk Register 'access' speculative; no content details contradicting claims. Hindsight bias via crash/Quinn Report. Cover-up post-Oct 2 suggests recklessness then, but not for Class Period statements. No strong inference over mismanagement/optimism."
        },
        {
          "claim": "COUNT II: Section 10(b)/Rule 10b-5(a)/(c) against GM, Cruise, and Individual Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Scheme allegations (misleading media/video post-crash, prior downplaying) lack particularized facts of intent/recklessness for ongoing fraud. Relies on same weak scienter as Count I: corporate culture, CW hearsay, no defendant-specific contemporaneous knowledge. Post-crash actions show opacity but equally explainable as crisis mismanagement, not fraudulent scheme from Class Period start. No strong inference."
        },
        {
          "claim": "COUNT III: Section 20(a) against Barra, Jacobson, Parks (control of GM)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed underlying Section 10(b) claims; requires primary violation."
        },
        {
          "claim": "COUNT IV: Section 20(a) against Individual Defendants (control of Cruise)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed underlying Section 10(b) claims; requires primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 64016,
      "completion_tokens": 552,
      "total_tokens": 65820
    },
    "case_id": "mied-4-23-cv-13132"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint pleads with particularity facts giving rise to a strong inference of scienter for the Section 10(b)/Rule 10b-5 claims, including specific contemporaneous rejection letters and regulator communications directed to named individual defendants (Sloan, Duke, Shrewsberry, Parker), internal emails acknowledging deficiencies and materiality to investors received by them, personal involvement in extension requests and toned-down disclosures, Sloan's private apology for misstatements, and subsequent false assurances despite knowledge of non-approval of Stage 1 plans. These facts show actual knowledge of falsity at the time of statements claiming 'plans in place,' 'executing/implementing,' and 'in compliance,' rendering innocent explanations (e.g., optimistic progress views) less plausible. Count I sustained; Count II sustained as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Section 10(b) of the Exchange Act and Rule 10b-5 (against Wells Fargo, Sloan, Parker, Duke, Shrewsberry)",
          "ruling": "sustained",
          "scienter_analysis": "Particularized facts demonstrate defendants' actual knowledge of falsity: FRB rejection letters (May 7, 2018; March 11, 2019) addressed to Sloan/Duke post-submissions, describing plans as 'materially incomplete'/'insufficient'; OCC rejections (July 24, 2018; Nov. 21, 2018) to Duke/Parker; May 13, 2018 email to Sloan/Parker/Shrewsberry on FRB rebuke; internal admissions (e.g., 'totally biffed it'; 'work in progress'); Sloan/Duke collusion to remove 'substantial work remaining' disclosure (Mar. 2019); Sloan's post-testimony apology to FRB (Mar. 12, 2019) for false 'compliance' claim despite March 11 rejection. Defendants continued specific false statements (e.g., Shrewsberry May 30/June 13 post-May 7; Sloan Dec. 4/Jan. 15 post-multiple rejections) knowing no Stage 1 approval, creating strong scienter inference over plausible non-culpable views."
        },
        {
          "claim": "Count II: Section 20(a) of the Exchange Act (against Insider Defendants: Sloan, Shrewsberry, Scharf, Parker, Duke)",
          "ruling": "sustained",
          "scienter_analysis": "Derivative of sustained Count I primary violation; control alleged via senior positions, Operating Committee/Risk Committee roles, personal regulator contacts, and oversight of compliance submissions/statements."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 50338,
      "completion_tokens": 535,
      "total_tokens": 52736
    },
    "case_id": "nysd_20_cv_04494"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The motion to dismiss is GRANTED. All claims are dismissed with prejudice. The complaint fails to plead particularized facts giving rise to a strong inference of scienter as required by the PSLRA for the Section 10(b)/Rule 10b-5 claim. Section 20(a) claims are dismissed as derivative. The Section 14(a)/Rule 14a-9 claim fails to plead material misstatements or omissions with particularity, relying on conclusory allegations and fraud-by-hindsight.",
      "claim_rulings": [
        {
          "claim": "First Claim: Violations of Section 10(b) of the Exchange Act and Rule 10b-5 Against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations show defendants knew statements were false when made. Allegations of 'core operations,' positions/access to info, motive (shares/promotion), resignations, and later investigation are conclusory, amount to fraud-by-hindsight, and rely on general corporate knowledge. A $30M overstatement is material but lacks specifics tying individual defendants to actual knowledge of falsity at statement time (e.g., no documents, witness accounts). Innocent explanations (sloppy accounting discovered later, Dickinson acting alone per cited lawsuit) equally plausible. No strong inference of scienter."
        },
        {
          "claim": "Second Claim: Violations of Section 20(a) of the Exchange Act Against the Individual Defendants (derivative of Section 10(b)/Rule 10b-5)",
          "ruling": "dismissed",
          "scienter_analysis": "Dismissed as derivative of dismissed underlying Section 10(b)/Rule 10b-5 claim, which fails PSLRA scienter pleading."
        },
        {
          "claim": "Third Claim: Violation of Section 14(a) of the Exchange Act and Rule 14a-9 Against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Although Section 14(a) requires negligence, not PSLRA scienter, claims sound in fraud and are subject to Rule 9(b) particularity. Proxy disclosures extensively warned of regulatory risks; no particularized facts show known non-compliance or internal control failures at filing (Oct. 2021), only later (2022) investigation. Revenue projections ($71M) near initial reports ($68.5M); no facts of known falsity then. Hindsight from restatements/resignations insufficient."
        },
        {
          "claim": "Fourth Claim: Violation of Section 20(a) of the Exchange Act Against the Individual Defendants (derivative of Section 14(a)/Rule 14a-9)",
          "ruling": "dismissed",
          "scienter_analysis": "Dismissed as derivative of dismissed underlying Section 14(a)/Rule 14a-9 claim."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 27127,
      "completion_tokens": 569,
      "total_tokens": 29159
    },
    "case_id": "nysd_22-cv-07111"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead scienter with particularity under the PSLRA for the Section 10(b)/Rule 10b-5 claim. Allegations of FDA concerns conveyed in meetings are summarized without specific contemporaneous evidence (e.g., meeting minutes, emails) showing defendants knew statements were false when made. Reliance on FDA's later public statements at ODAC constitutes impermissible 'fraud by hindsight.' Optimistic statements about dose optimization, study progress, and FDA 'alignment' amid known risks are equally explained by legitimate business judgment in biotech development. Motive (cash needs, ATM sales) and small insider sales are not compelling. Item 303 omission claims fail for lack of scienter and materiality. Section 20(a) claims dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Violation of Section 10(b) of the Exchange Act and Rule 10b-5 Against All Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts show defendants knew statements (e.g., dose 'optimized,' PINNACLE 'initiated' with 'patients being randomized,' 'aligned' with FDA) were false when made. Pre- and in-Class Period FDA meetings are alleged in conclusory terms ('repeatedly told... data inadequate, no agreement') without specifics proving actual knowledge of falsity. FDA's ODAC/briefing disclosures of prior concerns do not retroactively establish contemporaneous knowledge. 'At own risk' warnings suggest risk awareness, not deception. Evasive enrollment responses and press releases are not literally false if sites were activating. Corporate scienter imputed only if primary violation; none here. Innocent explanations (optimism, site activation delays common in trials) at least as plausible as fraud."
        },
        {
          "claim": "Count II: Violation of Section 20(a) of the Exchange Act Against the Individual Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b) claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 23587,
      "completion_tokens": 411,
      "total_tokens": 25157
    },
    "case_id": "nysd_22_cv_10292"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead the requisite strong inference of scienter under the PSLRA for any defendant with respect to the alleged misstatements. While Capone personally touted his educational background, the complaint relies on conclusory allegations of knowledge, general access to information, and fraud-by-hindsight based on post-Class Period revelations rather than contemporaneous particularized facts demonstrating actual knowledge of falsity (e.g., no internal documents, confidential witness accounts, or specific contradictory information available to defendants at the time). Innocent explanations—optimistic projections on contract values during an ongoing bidding process, inadvertent bio errors propagated without verification, and imprecise statements on Medicaid processes—are equally or more plausible than fraudulent intent, particularly given Capone's framing of the degree issue as an 'error' and apology. No particularized facts show Vashovsky or Oberholzer knew Capone's credentials were fabricated. Accordingly, Count I is dismissed, requiring dismissal of derivative Count II.",
      "claim_rulings": [
        {
          "claim": "Count I: Violations of §10(b) of the 1934 Act and SEC Rule 10b-5 (Against All Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized factual allegations show any defendant knew the statements were false when made. Education claims rely on Capone's repetition and later admission, but lack specific contemporaneous evidence of his knowledge beyond speculation; innocent bio error plausible. Contract and Medicaid claims are classic hindsight (later-reported values/sign-up clarifications prove falsity, but no facts defendants knew true values/abilities at time). Vashovsky/Oberholzer/Oberholzer rely solely on positions, oversight, and signing filings (group pleading/general knowledge). No strong inference over innocent explanations like bidding optimism or unverified resumes."
        },
        {
          "claim": "Count II: Violations of §20(a) of the 1934 Act (Against All Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Count I; no underlying §10(b) violation adequately pleaded."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 16095,
      "completion_tokens": 415,
      "total_tokens": 22064
    },
    "case_id": "nysd_23_cv_9476"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "Exchange Act claims (Counts I-III) dismissed for failure to plead scienter with particularized facts creating a strong inference of intent or recklessness; allegations rely on pre-Class Period former employee accounts, generalized industry practices ('should have known'), core operations doctrine, and hindsight from later disclosures, with equally plausible innocent explanations (e.g., COVID-era commitments to secure supply, customer-driven inventory builds). Securities Act claims (Counts IV-V) sustained; statements in Offering Documents plausibly misleading regarding customer commitments, shipment practices, and demand trends under Sections 11/15 standards (no scienter required).",
      "claim_rulings": [
        {
          "claim": "Count I: Section 10(b)/Rule 10b-5(b) against Mobileye and Executive Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized facts showing defendants' actual knowledge of falsity when statements made; FE 2's account (Shashua/Heller awareness) ends Dec. 2022 pre-Class Period; relies on chain-of-command speculation, industry EDI standards ('must have received reports' = 'should have known'), and general monitoring claims; motive to meet guidance generic; innocent inferences (business judgments on commitments amid supply shortages) at least as compelling as fraud."
        },
        {
          "claim": "Count II: Section 10(b)/Rules 10b-5(a)/(c) against Mobileye and Executive Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Scheme liability requires same PSLRA scienter; no specific contemporaneous facts of knowing scheme to defraud (e.g., no internal docs, post-Class Period FEs); channel stuffing plausibly legitimate revenue management; 'impossible to adjust' admitted later but framed as customer commitments, not deception."
        },
        {
          "claim": "Count III: Section 20(a) against Executive Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b) claims; no underlying violation."
        },
        {
          "claim": "Count IV: Section 11 against Mobileye, Shashua, Heller",
          "ruling": "sustained",
          "scienter_analysis": "N/A (negligence/strict liability; no scienter required); Offering Documents plausibly omit known trends (excess inventory, inflexible commitments) under Item 303 and misleadingly state shipments 'depend upon market conditions' despite fixed obligations."
        },
        {
          "claim": "Count V: Section 15 against Shashua, Heller",
          "ruling": "sustained",
          "scienter_analysis": "N/A (control person liability derivative of Section 11; adequately pleaded via signing roles and senior positions)."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 43285,
      "completion_tokens": 546,
      "total_tokens": 45535
    },
    "case_id": "nysd_24_cv_310"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint fails to plead particularized facts giving rise to a strong inference of scienter under the PSLRA for the Section 10(b)/Rule 10b-5 claim. Allegations rely on confidential witness accounts from mid-level employees, generalized access to internal reports (SalesLink, PRISM, IATA), and post-Class Period admissions, which constitute speculation, 'fraud by hindsight,' and group pleading rather than specific contemporaneous knowledge of falsity by individual defendants. Optimistic statements about the NDC strategy are equally explained by aggressive business execution and hope for customer adaptation amid disclosed risks. Section 10(b) claim dismissed; Section 20(a) claim dismissed as derivative.",
      "claim_rulings": [
        {
          "claim": "Count I: Violation of Section 10(b) of the Exchange Act and Rule 10b-5 (against all Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "No particularized allegations show any defendant knew specific statements were false when made. CW1 and CW2 (mid-level sales roles) describe internal data trends and declines from mid-2023, but provide no evidence Individual Defendants reviewed contradicting data contemporaneous to statements (e.g., no emails, meeting notes, or specific report citations attributing knowledge to Isom, May, or Raja). Claims of 'Defendants knew' via 'data available to them' are conclusory. Weekly IATA meetings attended by VPs (not Individual Defendants); Raja's alleged access speculative. Post-period admissions (e.g., Isom's Q1 2024 'deviation' knowledge) are hindsight; equally plausible innocent mismanagement/optimism. Many statements puffery ('encouraged,' 'pleased') or forward-looking with risk disclosures. Core operations inference weak; no GAAP violations or SARs. No strong inference over innocent explanations."
        },
        {
          "claim": "Count II: Violation of Section 20(a) of the Exchange Act (against Individual Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Derivative of dismissed Section 10(b) claim; no underlying primary violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 54955,
      "completion_tokens": 428,
      "total_tokens": 56507
    },
    "case_id": "txnd-4_24-cv-00673"
  },
  {
    "model": "grok",
    "model_id": "xai/grok-4-1-fast-reasoning",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "The complaint adequately pleads particularized facts supporting a strong inference of scienter for the Section 10(b)/Rule 10b-5 claim, primarily through detailed allegations from multiple former employees (e.g., FE-1's specific warnings to Giraud in meetings, directives to ignore higher risks, weekly executive meetings involving Leach, Giraud, and Schroer, and real-time data showing poor performance), contradicting specific Class Period statements by individual defendants about validated spacing, modeled risks, and expected results. These facts show actual knowledge or reckless disregard at the time of statements, outweighing innocent explanations like good-faith testing. No reliance on conclusory allegations, hindsight, or speculation. Section 20(a) sustained as derivative of primary violation.",
      "claim_rulings": [
        {
          "claim": "COUNT I: Violation of Section 10(b) of the Exchange Act and Rule 10b-5 Against All Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Particularized allegations from FE-1 detail Giraud's direct knowledge via led budgeting meetings (2017-2018), ignored warnings on tight spacing risks and improper low-risk profiles in Aries database (contradicting Giraud's Oct. 31, 2018 statement on baked-in forecasts), and real-time pressure/production data showing early Dominator failure (contradicting Leach/Giraud Feb./May 2019 statements). Weekly exec meetings (Leach/Giraud/Schroer) and chain of command (to Harper/Leach) extend to others. FE-3/4/5/8 confirm ignored warnings/protests company-wide. Defendants' detailed public statements indicate hands-on knowledge. Holistic view yields strong inference of intent/recklessness over plausible innocence (e.g., basic engineering ignored)."
        },
        {
          "claim": "COUNT II: Violation of Section 20(a) of the Exchange Act Against the Individual Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Derivative of sustained Section 10(b)/Rule 10b-5 claim; culpable participation via positions, signing 10-Ks, and specific statements/oversight alleged."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 66230,
      "completion_tokens": 444,
      "total_tokens": 68739
    },
    "case_id": "txsd-4-21-cv-02473"
  }
]